Sean McCutcheon Analyst Performance

Vice President, Biotechnology Equity Research at Raymond James Financial

Sean McCutcheon is a stock analyst at Raymond James Financial in the medical sector, covering 5 publicly traded companies. Over the past year, Sean McCutcheon has issued 6 stock ratings, including strong buy and buy recommendations. While full access to Sean McCutcheon's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Sean McCutcheon's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 6 Last 0 Years
Buy Recommendations: 100.00% 6 Buy Ratings
Companies Covered: 5 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	33.3%	2 ratings
Buy	66.7%	4 ratings
Hold	0.0%	0 ratings
Sell	0.0%	0 ratings

Out of 6 total stock ratings issued by Sean McCutcheon at Raymond James Financial, the majority (66.7%) have been Buy recommendations, followed by 33.3% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	5 companies

Sean McCutcheon, an analyst at Raymond James Financial, currently covers 5 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 5 companies	100.0%

Sean McCutcheon of Raymond James Financial specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 5 companies	100.0%

About Sean McCutcheon

Sean McCutcheon joined Raymond James in 2021 as an associate covering biotechnology. Prior to Raymond James he was a postdoctoral fellow in the Department of Neuroscience at Albert Einstein College of Medicine focused on neuro-oncology. Prior to that he received his Ph.D. in biomedical engineering from The City College of New York, developing microfluidics to interrogate cell communication in the context of bone homeostasis, and obtained his Bachelor of Science degree in materials science and engineering from The Ohio State University, graduating with honors. His research in cancer and bone biology prior to joining Wall Street resulted in eight authored or co-authored peer-reviewed publications.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RVMD Revolution Medicines	10/17/2025	Boost Price Target	$55.73	$76.00	Strong-Buy
RVMD Revolution Medicines	9/12/2025	Initiated Coverage	$46.24	$72.00	Strong-Buy
JANX Janux Therapeutics	7/11/2025	Initiated Coverage	$25.61	$65.00	Outperform
VIR Vir Biotechnology	7/11/2025	Upgrade	$5.93	$12.00	Moderate Buy
CMPX Compass Therapeutics	7/1/2025	Upgrade	$2.60	$9.00	Outperform
BDTX Black Diamond Therapeutics	7/1/2025	Upgrade	$2.48	$11.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.